Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Pharma
Gilead writes $2.4B off Trodelvy as CEO underscores focus
Despite the $2.4 billion impairment charge, Gilead believes Trodelvy has a future in NSCLC.
Angus Liu
Apr 26, 2024 11:21am
Top 20 pharma companies by 2023 revenue
Apr 15, 2024 3:00am
Gilead enlists Raheem DeVaughn in HIV education, prevention work
Apr 12, 2024 7:10am
Gilead locks in with dancer for HIV awareness voguing workshop
Apr 3, 2024 7:35am
Teva snares up to $150M in Abingworth funding for inhaler program
Apr 1, 2024 10:51am
Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M
Mar 19, 2024 1:13pm